Shin Poong Pharm.Co.,Ltd. (019170.KS)
KRW 10370.0
(-5.04%)
KRW 10370.0
(-5.04%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 46.15 Billion KRW | 2293.41% |
| 2022 | 1.92 Billion KRW | 63.31% |
| 2021 | 1.18 Billion KRW | -33.86% |
| 2020 | 1.78 Billion KRW | -98.32% |
| 2019 | 106.49 Billion KRW | -0.88% |
| 2018 | 107.44 Billion KRW | -4.55% |
| 2017 | 112.56 Billion KRW | -7.31% |
| 2016 | 121.43 Billion KRW | -22.2% |
| 2015 | 156.09 Billion KRW | -0.57% |
| 2014 | 156.98 Billion KRW | 8.76% |
| 2013 | 144.34 Billion KRW | 9.81% |
| 2012 | 131.44 Billion KRW | -5.35% |
| 2011 | 138.88 Billion KRW | 11.13% |
| 2010 | 124.97 Billion KRW | 5.54% |
| 2009 | 118.41 Billion KRW | 22.32% |
| 2008 | 96.8 Billion KRW | 45.46% |
| 2007 | 66.54 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 45.98 Billion KRW | -0.37% |
| 2024 Q2 | 45.23 Billion KRW | -1.63% |
| 2023 Q1 | 31.6 Billion KRW | 1539.22% |
| 2023 Q3 | 46.46 Billion KRW | 48.15% |
| 2023 FY | 46.15 Billion KRW | 2293.41% |
| 2023 Q2 | 31.36 Billion KRW | -0.77% |
| 2023 Q4 | 46.15 Billion KRW | -0.69% |
| 2022 Q2 | 2.26 Billion KRW | 43.45% |
| 2022 Q4 | 1.92 Billion KRW | -16.22% |
| 2022 FY | 1.92 Billion KRW | 63.31% |
| 2022 Q1 | 1.58 Billion KRW | 33.83% |
| 2022 Q3 | 2.3 Billion KRW | 1.54% |
| 2021 Q4 | 1.18 Billion KRW | -15.17% |
| 2021 Q1 | 1.55 Billion KRW | -13.15% |
| 2021 Q2 | 11.36 Billion KRW | 633.0% |
| 2021 FY | 1.18 Billion KRW | -33.86% |
| 2021 Q3 | 1.39 Billion KRW | -87.75% |
| 2020 Q3 | 107.2 Billion KRW | 0.36% |
| 2020 Q2 | 106.82 Billion KRW | -0.04% |
| 2020 Q1 | 106.86 Billion KRW | 0.35% |
| 2020 FY | 1.78 Billion KRW | -98.32% |
| 2020 Q4 | 1.78 Billion KRW | -98.33% |
| 2019 Q1 | 108.53 Billion KRW | 1.02% |
| 2019 FY | 106.49 Billion KRW | -0.88% |
| 2019 Q4 | 106.49 Billion KRW | -0.05% |
| 2019 Q3 | 106.54 Billion KRW | -1.39% |
| 2019 Q2 | 108.04 Billion KRW | -0.45% |
| 2018 Q2 | 110.34 Billion KRW | -1.06% |
| 2018 Q4 | 107.44 Billion KRW | -1.67% |
| 2018 Q3 | 109.27 Billion KRW | -0.97% |
| 2018 FY | 107.44 Billion KRW | -4.55% |
| 2018 Q1 | 111.52 Billion KRW | -0.93% |
| 2017 Q3 | 115.34 Billion KRW | -1.44% |
| 2017 Q1 | 118.85 Billion KRW | -2.12% |
| 2017 FY | 112.56 Billion KRW | -7.31% |
| 2017 Q4 | 112.56 Billion KRW | -2.41% |
| 2017 Q2 | 117.03 Billion KRW | -1.54% |
| 2016 FY | 121.43 Billion KRW | -22.2% |
| 2016 Q3 | 128.38 Billion KRW | -3.93% |
| 2016 Q4 | 121.43 Billion KRW | -5.41% |
| 2016 Q2 | 133.64 Billion KRW | -10.96% |
| 2016 Q1 | 150.09 Billion KRW | -3.84% |
| 2015 Q3 | 151.44 Billion KRW | -2.32% |
| 2015 Q1 | 151.07 Billion KRW | -3.77% |
| 2015 FY | 156.09 Billion KRW | -0.57% |
| 2015 Q4 | 156.09 Billion KRW | 3.07% |
| 2015 Q2 | 155.04 Billion KRW | 2.63% |
| 2014 FY | 156.98 Billion KRW | 8.76% |
| 2014 Q3 | 151.35 Billion KRW | 0.92% |
| 2014 Q4 | 156.98 Billion KRW | 3.72% |
| 2014 Q2 | 149.96 Billion KRW | 0.89% |
| 2014 Q1 | 148.64 Billion KRW | 2.98% |
| 2013 Q1 | 134.26 Billion KRW | 2.14% |
| 2013 Q4 | 144.34 Billion KRW | -3.04% |
| 2013 FY | 144.34 Billion KRW | 9.81% |
| 2013 Q2 | 146.33 Billion KRW | 8.99% |
| 2013 Q3 | 148.86 Billion KRW | 1.73% |
| 2012 Q1 | 128.76 Billion KRW | 0.0% |
| 2012 Q4 | 131.44 Billion KRW | 0.0% |
| 2012 FY | 131.44 Billion KRW | -5.35% |
| 2011 Q2 | 134.27 Billion KRW | -1.38% |
| 2011 FY | 138.88 Billion KRW | 11.13% |
| 2011 Q3 | 138.91 Billion KRW | 3.45% |
| 2011 Q1 | 136.15 Billion KRW | 0.0% |
| 2010 Q2 | 124.63 Billion KRW | 4.89% |
| 2010 FY | 124.97 Billion KRW | 5.54% |
| 2010 Q3 | 121.79 Billion KRW | -2.28% |
| 2010 Q1 | 118.81 Billion KRW | 0.0% |
| 2009 Q2 | 110.13 Billion KRW | 5.2% |
| 2009 FY | 118.41 Billion KRW | 22.32% |
| 2009 Q3 | 115.58 Billion KRW | 4.95% |
| 2009 Q1 | 104.69 Billion KRW | 0.0% |
| 2008 FY | 96.8 Billion KRW | 45.46% |
| 2008 Q2 | 80.23 Billion KRW | 10.39% |
| 2008 Q1 | 72.68 Billion KRW | 0.0% |
| 2008 Q3 | 91.18 Billion KRW | 13.64% |
| 2007 Q2 | 60.72 Billion KRW | 15.52% |
| 2007 Q3 | 63.98 Billion KRW | 5.36% |
| 2007 FY | 66.54 Billion KRW | 0.0% |
| 2007 Q1 | 52.56 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -17.114% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 93.33% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 87.92% |
| HANDOK Inc. | 300.01 Billion KRW | 84.617% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -50.516% |
| Yuhan Corporation | 230.07 Billion KRW | 79.94% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 88.652% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -7650.217% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 91.944% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -3476.162% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 45.806% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | -6.652% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | 48.994% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -73.939% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -17.114% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -19281.1% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 79.493% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | 74.502% |
| JW Holdings Corporation | 554.58 Billion KRW | 91.678% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 78.814% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 79.0% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 72.897% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -17.719% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | 73.76% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | 45.682% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -17.114% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 80.415% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 90.174% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 72.897% |
| Yuhan Corporation | 230.07 Billion KRW | 79.94% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | 73.328% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | 30.996% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 90.136% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 72.897% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | 61.099% |
| Korea United Pharm Inc. | 40.33 Billion KRW | -14.409% |
| CKD Bio Corp. | 146.92 Billion KRW | 68.589% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | 68.4% |
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | 4.36% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -7202.148% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | 0.0% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 90.139% |
| Boryung Corporation | 204.21 Billion KRW | 77.401% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | 41.865% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 45.806% |
| JW Lifescience Corporation | 46.31 Billion KRW | 0.348% |